Investigating a new target for reducing mucus production in cystic fibrosis
Pre-Clinical Evaluation of IRE1beta as a Novel Therapeutic Target for Cystic Fibrosis Airway Mucus Production
This study is looking at how a protein called IRE1beta affects mucus production in the lungs of children with cystic fibrosis, with the hope of finding new treatments to help reduce the extra mucus that makes it hard for them to breathe.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10906092 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific protein, IRE1beta, contributes to excessive mucus production in the lungs of children with cystic fibrosis (CF). By studying the role of IRE1beta in airway epithelial cells, the research aims to identify potential therapies that could reduce mucus overproduction, which is a significant problem for CF patients. The approach involves examining the molecular mechanisms behind mucin synthesis and how IRE1beta can be targeted to alleviate airway obstruction caused by mucus. If successful, this could lead to new treatment options for young patients suffering from CF-related respiratory issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are young children diagnosed with cystic fibrosis who experience excessive mucus production in their airways.
Not a fit: Patients with cystic fibrosis who do not exhibit significant mucus overproduction or those with advanced lung disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic options to reduce mucus production in cystic fibrosis patients, improving their respiratory health.
How similar studies have performed: While the specific targeting of IRE1beta in cystic fibrosis is a novel approach, similar strategies targeting mucin production have shown promise in other respiratory conditions.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Ribeiro, Carla Maria Pedrosa — Univ of North Carolina Chapel Hill
- Study coordinator: Ribeiro, Carla Maria Pedrosa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.